RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1252
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals but lowers the price target from $1282 to $1252.
September 24, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Regeneron Pharmaceuticals but reduces the price target from $1282 to $1252, indicating a slight decrease in expected valuation.
The Outperform rating suggests continued confidence in Regeneron's performance, but the lowered price target indicates a slight reduction in expected valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100